Literature DB >> 483361

Action of complement in the lysis of mouse sarcoma cells sensitized with H-2 alloantibody.

A B Reske-Kunz, M P Scheid, J Abbott, L J Metakis, M J Polley, E A Boyse.   

Abstract

A modified cytotoxicity assay was adapted from classical erythrocytolytic assays, in which complement components were added in sequence to antibody-sensitized cells. This assay was applied to a model system in which mouse sarcoma cells were sensitized with H-2 alloantibody. The stepwise presentation of complement components combined with the stabilization of C2 by iodine treatment considerably augmented the lytic efficiency of human complement. More generally, the techniques adopted for this study provide a new model for obtaining basic information about selective reaction steps concerned in lysis of nucleated cells by alloantibody and complement. Comparisons of the lysis of sheep erythrocytes by xenoantibody with the lysis of mouse sarcoma cells by H-2 alloantibody, in our assay system with oxidized or untreated human complement, disclosed a difference in the kinetics of C142 formation, manifest in a lag phase and a protracted tmax for the sarcoma cells. These data may suggest that multiple complement-mediated functional lesions are necessary for immune lysis of nucleated cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 483361     DOI: 10.1097/00007890-197908000-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics.

Authors:  C L Koski; L E Ramm; C H Hammer; M M Mayer; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

2.  Esr, a second locus in the house mouse controlling esterase-5.

Authors:  O H von Deimling; J Otto; A B Reske-Kunz
Journal:  Biochem Genet       Date:  1982-04       Impact factor: 1.890

3.  Human megakaryocytes. V. Changes in the phenotypic profile of differentiating megakaryocytes.

Authors:  R B Levene; J M Lamaziere; H E Broxmeyer; L Lu; E M Rabellino
Journal:  J Exp Med       Date:  1985-03-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.